ArticleZhonghua nei ke za zhi2020
[China cholesterol education program (CCEP) expert advice for the management of dyslipidaemias to reduce cardiovascular risk (2019)].
Article in Zhonghua nei ke za zhi, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT04945122. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Comparison of Atorvastatin and Pitavastatin on the Effect of HbA1c in Acute Myocardial Infarction (AMI) Patients With Abnormal Glucose Metabolism: a Multicenter Prospective Randomized Clinical Trial
Study on the Composite Endpoint Event of PCSK9 Inhibitor in Patients With Very High Risk of ASCVD and Cancer
Who cites it
15 citing papers in PubMed.
- Efficacy and Safety of Ongericimab in Chinese Patients With Primary Hypercholesterolemia and Mixed Dyslipidemia.Journal of the American Heart Association · 2024 · on this mapTrial
- Association of Life's Essential 8 with albuminuria in a Northern Chinese population: a cross-sectional study.Scientific reports · 2026Article
- Cost-effectiveness of inclisiran in patients with atherosclerotic cardiovascular disease from Chinese healthcare perspective.PloS one · 2026Article
- Beyond LDL-C: discordant small dense LDL cholesterol stratifies hypertension risk in a Chinese longitudinal cohort.Lipids in health and disease · 2025Article
- Liver indicators affecting the relationship between BMI and hypertension in type 2 diabetes: a mediation analysis.Diabetology & metabolic syndrome · 2024Article
- Cognition and influencing factors of secondary prevention in patients with ischemic stroke 1 year after discharge in Southwest China: a cross-sectional survey.Frontiers in neurology · 2024Article
- Degree of Blood Glucose Control and Risk of Hypertension in Chinese Adults with T2DM: A Cross-Sectional Study.Diabetes, metabolic syndrome and obesity : targets and therapy · 2024Article
- Methodology and results of cost-effectiveness of LDL-C lowering with evolocumab in patients with acute myocardial infarction in China.Cost effectiveness and resource allocation : C/E · 2023Article
- Remnant cholesterol but not LDL cholesterol is associated with 5-year bleeding following percutaneous coronary intervention.iScience · 2023Article
- Age at diagnosis, diabetes duration and the risk of cardiovascular disease in patients with diabetes mellitus: a cross-sectional study.Frontiers in endocrinology · 2023Article
- Trends of Hypercholesterolemia Change in Shenzhen, China During 1997-2018.Frontiers in public health · 2022Article
- Non-fasting Changes in Blood Lipids After Three Daily Meals Within a Day in Chinese Inpatients With Cardiovascular Diseases.Frontiers in cardiovascular medicine · 2022Article
- Atherosclerotic Cardiovascular Disease Risk and Lipid-Lowering Therapy Requirement in China.Frontiers in cardiovascular medicine · 2022Article
- Effects of Evolocumab Added to Moderate-Intensity Statin Therapy in Chinese Patients With Acute Coronary Syndrome: The EMSIACS Trial Study Protocol.Frontiers in physiology · 2021Article
- Role of Lipid-Lowering Therapy in Low-Density Lipoprotein Cholesterol Goal Attainment: Focus on Patients With Acute Coronary Syndrome.Journal of cardiovascular pharmacology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The prevalence of dyslipidemia in Chinese adult is increasing dramatically, which poses a severe challenge to the prevention and treatment of atherosclerotic cardiovascular diseases. In recent years, a series of new research results have been published, providing a lot of new information for the management strategy of dyslipidemia. In order to apply these new research results to clinical practice for the further prevention and treatment of dyslipidemia more reasonably and effectively, the China Cholesterol Education Program (CCEP) Working Committee organized joint expert meeting and revised the "Expert Advice on Prevention and Treatment of Dyslipidemia in China Cholesterol Education Program 2014", in which a new classification standard for cardiovascular risk stratification has been proposed, and the target value of lipid-lowering therapy has been updated.
Indexed as
Identifiers
31887831What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.